Furthermore, FTD-treated cells had lower expression of B2M, a gene encoding the β2M protein responsible for stabilizing the HLA-I complex34, and TAP1, a component of the antigen-presenting machinery (APM) whose down-regulation is associated with tumor immune escape and worse prognosis in CRC patients35. The gene discussed is B2M; the disease is neoplasm.